Key Metrics 
10 Yrs X-Ray 
Profit & Loss 
Valuation 
Analyst Note 
Balance Sheet 
Cash Flow 
Financial Ratio 
Qtr. Results 
News 
About
Tonira Pharma Ltd (530155)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530155 NSE: Pharmaceuticals & Drugs | Small Cap | Tonira Pharma Share Price
BSE Share Price
Not Listed
Not Listed
Tonira Pharma Ltd (530155)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530155 NSE: Pharmaceuticals & Drugs | Small Cap | Tonira Pharma Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹16 Cr.
Current Price
₹0
52-Week Low / High
₹19 / 20
TTM EPS
₹-4.2
TTM Sales
₹33.5 Cr.
Book Value per Share
₹12.5
P/E Ratio
0.00
Industry PE
50
Price to Book (P/B)
1.58
Price to Sales (P/S)
0.47
EV/EBITDA
33.96
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
-15.65%
Return on Capital Employed (ROCE)
1.97%
Return on Assets (ROA)
-3.87%
Operating Profit Margin
8.1%
Net Profit Margin
-6.89%
Gross Profit Margin
2.9%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-18.12%
Operating Profit Growth (1 Year)
-
-62.28%
Net Profit Growth (1 Year)
-
-303.92%
Asset Quality
Promoter Holding
37.27%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹2 Cr.
Equity
₹7.9 Cr.
Face Value
₹10
All Time Low / High
₹0.80 / 50.30
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 13.2% | 18.1% | 5.9% | 10.8% | 11% | 11.4% | -17.3% | 7.8% | 9.9% | 2% | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 19.4 | 24 | 26.2 | 22.5 | 29.4 | 36.8 | 32.6 | 41.3 | 36.9 | 30.2 | 33 |
| Sales YoY Gr. | - | 23.3% | 9.1% | -13.8% | 30.3% | 25.2% | -11.5% | 26.8% | -10.7% | -18.1% | - |
| Adj EPS ⓘ | 2.4 | 3.4 | 0.1 | 1.8 | 2.3 | 2.2 | -4.3 | 2.5 | 0.8 | -3.8 | -4.2 |
| YoY Gr. | - | 44.5% | -96.5% | 1425% | 25.1% | -6.1% | -300.5% | NA | -66.9% | -565.9% | - |
| BVPS (₹) ⓘ | 15.4 | 16.5 | 17.5 | 21 | 23 | 24.7 | 17.5 | 16.4 | 18.1 | 15.4 | 12.5 |
| Adj Net Profit ⓘ | 1.9 | 2.7 | 0.1 | 1.5 | 1.8 | 1.7 | -3.4 | 2 | 0.7 | -3 | -3 |
| Cash Flow from Ops. ⓘ | 2.8 | 4.5 | 2.7 | 3.7 | -0.6 | 5.1 | -7.1 | 3.8 | 7.5 | -0.9 | - |
| Debt/CF from Ops. ⓘ | 2.1 | 0.8 | 2.5 | 4.2 | -37.7 | 3.9 | -4.1 | 7.1 | 4.2 | -39.4 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 5% | 0.6% | -2.5% | -18.1% | ||||
| Adj EPS ⓘ | -205.4% | -210.8% | NA | -565.9% | ||||
| BVPSⓘ | 0% | -7.7% | -4% | -14.5% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 16.2 | 21 | 0.7 | 9.4 | 10.3 | 8.9 | -20 | 14.4 | 4.8 | -22.8 | -30.2 |
| Op. Profit Mgn % ⓘ | 6.7 | 7.3 | 5.3 | 17.4 | 21.8 | 19.3 | -3.1 | 23.9 | 17.2 | 8.1 | 0.7 |
| Net Profit Mgn % ⓘ | 9.7 | 11.4 | 0.4 | 6.4 | 6.2 | 4.6 | -10.5 | 4.8 | 1.8 | -10.1 | -10 |
| Debt to Equity ⓘ | 0.5 | 0.3 | 0.5 | 0.9 | 1.2 | 1 | 2.1 | 2.1 | 2.2 | 3 | - |
| Working Cap Days ⓘ | 219 | 182 | 157 | 186 | 185 | 189 | 240 | 211 | 248 | 314 | 269 |
| Cash Conv. Cycle ⓘ | 122 | 80 | 64 | 93 | 97 | 100 | 128 | 100 | 131 | 187 | 203 |
Profit And Loss
(All Figures are in Crores.)| PARTICULARS | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19.44 | 23.96 | 26.15 | 22.54 | 29.37 | 36.78 | 32.56 | 41.28 | 36.86 | 30.18 |
| Operating Expenses ⓘ + | 18.14 | 22.22 | 24.89 | 18.65 | 23.60 | 29.92 | 33.57 | 33.03 | 30.55 | 27.80 |
| Operating Profit ⓘ | 1.30 | 1.74 | 1.26 | 3.89 | 5.77 | 6.87 | -1.01 | 8.25 | 6.31 | 2.38 |
| Operating Profit Margin (%) | 6.7% | 7.3% | 4.8% | 17.2% | 19.6% | 18.7% | -3.1% | 20.0% | 17.1% | 7.9% |
| Other Income ⓘ + | 2.02 | 2.52 | 1.11 | 0.39 | 0.60 | 0.21 | 0.62 | 0.48 | 0.75 | 1.62 |
| Interest ⓘ | 0.84 | 0.51 | 0.55 | 0.47 | 1.25 | 1.81 | 2.10 | 3.60 | 2.88 | 3.14 |
| Depreciation ⓘ | 1 | 1.13 | 1.27 | 1.43 | 2.44 | 2.57 | 2.77 | 2.80 | 2.84 | 3.07 |
| Profit Before Tax ⓘ | 1.48 | 2.62 | 0.55 | 2.38 | 2.68 | 2.70 | -9.18 | -0.35 | 1.34 | -2.21 |
| Tax ⓘ | -0.41 | -0.11 | -0.17 | 0.72 | 0.96 | 1.06 | -3.36 | 0.39 | 0.32 | -0.12 |
| Profit After Tax | 1.89 | 2.73 | 0.72 | 1.66 | 1.72 | 1.64 | -5.83 | -0.74 | 1.02 | -2.08 |
| PAT Margin (%) | 9.7% | 11.4% | 2.8% | 7.4% | 5.9% | 4.5% | -17.9% | -1.8% | 2.8% | -6.9% |
| Adjusted EPS (₹) | 2.4 | 3.4 | 0.9 | 2.1 | 2.2 | 2.1 | -7.3 | -0.9 | 1.3 | -2.6 |
| Dividend Payout Ratio (%) | 0% | 29.10% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Valuation of Tonira Pharma - Standalone
Analyst's Notes
No data found!
Balance Sheet
(All Figures are in Crores.)| PARTICULARS | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 12.71 | 13.36 | 14.09 | 16.72 | 18.44 | 20.08 | 14.25 | 13.19 | 14.34 | 12.26 | |
| Debt + | 5.77 | 3.56 | 6.77 | 15.30 | 21.40 | 19.68 | 28.90 | 27.02 | 31.29 | 36.73 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 3.05 | 3.62 | 3.75 | 4.73 | 4.57 | 7.33 | 7.92 | 9.20 | 6.52 | 5.13 | |
| Others Liabilities ⓘ | -0.39 | 1.61 | 0.87 | 0.54 | 1.53 | 2.78 | -0.38 | 1.21 | 0.79 | 0.62 | |
| Total Liabilities ⓘ | 21.14 | 22.16 | 25.48 | 37.29 | 45.94 | 49.88 | 50.69 | 50.62 | 52.95 | 54.74 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 4.27 | 3.67 | 9.22 | 9.86 | 27.30 | 27.79 | 26.19 | 24.13 | 24.55 | 23.40 | |
| CWIP ⓘ | 3.95 | 5.54 | 4.43 | 14.49 | 0 | 0 | 0 | 0.09 | 0.54 | 1.21 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0.12 | 0.04 | 0.04 | 0.04 | 0.14 | 0.14 | |
| Inventories | 9.08 | 7.05 | 7.77 | 9.21 | 10.72 | 15.23 | 13.79 | 13.13 | 11.73 | 15.56 | |
| Trade Receivables | 1 | 1.17 | 2.43 | 1.91 | 5.57 | 4.03 | 5.42 | 7.47 | 6.33 | 3.81 | |
| Cash Equivalents | 0.24 | 0.37 | 0.58 | 0.70 | 0.27 | 0.35 | 1.58 | 0.55 | 3.08 | 2.22 | |
| Others Assets ⓘ | 2.59 | 4.35 | 1.05 | 1.11 | 1.96 | 2.44 | 3.67 | 5.21 | 6.57 | 8.40 | |
| Total Assets ⓘ | 21.14 | 22.16 | 25.48 | 37.29 | 45.94 | 49.88 | 50.69 | 50.62 | 52.95 | 54.74 | |
Cash Flow
(All Figures are in Crores.)| PARTICULARS | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 2.77 | 4.46 | 2.69 | 3.68 | -0.57 | 5.07 | -7.14 | 3.82 | 7.45 | -0.93 |
| Cash Flow From Investing Activity ⓘ + | -1.48 | -2.11 | -5.68 | -12.08 | -5.62 | -3.27 | -0.85 | -0.72 | -3.82 | -2.63 |
| Cash Flow From Financing Activity ⓘ + | -1.26 | -2.21 | 3.21 | 8.53 | 6.11 | -1.72 | 9.22 | -4.12 | -1.10 | 2.71 |
| Net Cash Flow ⓘ | 0.02 | 0.13 | 0.21 | 0.12 | -0.08 | 0.08 | 1.22 | -1.03 | 2.53 | -0.86 |
Financial Ratio
| PARTICULARS | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 16.99 | 21.56 | 5.35 | 10.87 | 9.85 | 8.65 | -34.82 | -5.54 | 7.48 | -15.65 |
| ROCE (%) | 13.23 | 18.06 | 5.89 | 10.82 | 10.97 | 11.41 | -17.27 | 7.83 | 9.86 | 1.97 |
| Asset Turnover Ratio | 0.97 | 1.13 | 1.14 | 0.73 | 0.72 | 0.79 | 0.66 | 0.82 | 0.72 | 0.56 |
| PAT to CFO Conversion(x) | 1.47 | 1.63 | 3.74 | 2.22 | -0.33 | 3.09 | N/A | N/A | 7.3 | N/A |
| Working Capital Days | ||||||||||
| Receivable Days | 27.70 | 16.20 | 24.20 | 34.60 | 45.70 | 46.20 | 51.80 | 56.50 | 68 | 60.90 |
| Inventory Days | 151.50 | 119.90 | 99.50 | 135.40 | 121.80 | 124.90 | 159.10 | 117.90 | 122.50 | 163.80 |
| Payable Days | 95.70 | 85.40 | 99.20 | 168 | 138.80 | 137 | 148.30 | 141.20 | 100.20 | 71.40 |
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Tonira Pharma Ltd FAQs
The current trading price of Tonira Pharma on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Tonira Pharma stood at ₹15.69 Cr
The latest P/E ratio of Tonira Pharma as of 31-Dec-1969 is 0.00.
The latest P/B ratio of Tonira Pharma as of 31-Dec-1969 is 1.58.
The 52-week high of Tonira Pharma is ₹19.90 and the 52-week low is ₹19.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Tonira Pharma is ₹33.49 ( Cr.) .
Data is not available for this company.
No data found
No data found
About Tonira Pharma Ltd
Tonira Pharma incorporated, in 1992, is engaged in the business of manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and intermediates.
The company's manufacturing locations at Nandesari and Ankleshwar are inspected and approved by PMDA Japan. With the USFDA approval of the Nandesari plant and PMDA Japan approvals of both the plants, the company will now have access to regulated markets for its APIs.
Tonira operates a state-of-the-art R&D Center at Nandesari, Vadodara District in Gujarat. The centre is continuously developing newer value-added APIs through innovative and cost-effective processes.
Tonira undertakes contract synthesis both on exclusive and non-exclusive basis. The company has the capability to provide contract research and manufacturing services to its customers.
Products
APIs- Under this, the company manufactures Atenolo, Aceclofenac, Benzbromarone, Benzarone, Desloratadine, Ebastine, Famotidine, Glimepiride, Loratadine, Meloxicam, Mosapride Citrate, Nifedipine, Ofloxacin, Quetiapine Fumarate, Sodium Alendronate, Tramadol HCI, Tamsulosin HCI and Zolpidem Tartrate.
Recognitions/Achievements
- Tonira Pharma has received WHO-GMP approval for its manufacturing facility.
- The company is recipient of export award for two successive years from DGFT.
- Its R&D centre is recognized by Department of Science & Technology, Government of India.
- The company has been recognised as an Export House by Government of India.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
